View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 16, 2020

Sanofi and Translate Bio find positive preclinical Covid-19 vaccine results

Sanofi’s vaccines global business unit Sanofi Pasteur and Translate Bio have reported preclinical trial results that showed mRNA-based vaccine candidate, MRT5500 induced a favourable immune response against SARS-CoV-2.

Sanofi’s vaccines global business unit Sanofi Pasteur and Translate Bio have reported preclinical trial results that showed mRNA-based vaccine candidate, MRT5500 induced a favourable immune response against SARS-CoV-2.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

These results support progressing the vaccine candidate into clinical development, with a Phase I / II trial expected to commence in the fourth quarter of this year.

Sanofi Pasteur and Translate Bio are developing MRT5500 as part of a partnership deal.

Four dose levels of the vaccine candidate were evaluated at 0.2µg, 1µg, 5µg and 10µg in mice using a two-dose schedule administered three weeks apart.

In non-human primates (NHPs), three dose levels of 15µg, 45µg and 135µg MRT5500 were analysed with a similar two-dose approach.

Data showed that the vaccine candidate induced dose-dependent levels of binding antibodies and neutralising antibodies specific to SARS-CoV-2 spike protein significantly higher than those observed in patients with Covid-19.

Moreover, MRT5500-immunised mice and NHPs demonstrated a Th1-biased T-cell response against SARS-CoV-2.

Translate Bio CEO Ronald Renaud said: “The preclinical results we report in this paper demonstrate the ability of MRT5500 to elicit a favourable immune response in both mice and non-human primates.

“Importantly, these results provide additional support for using our mRNA platform to potentially expedite the development of alternative approaches to traditional vaccines.”

In 2018, the companies signed a collaboration and exclusive license agreement to develop mRNA vaccines for up to five infectious disease pathogens.

Initially, the deal expanded in March to include the development of a novel mRNA vaccine for Covid-19.

Sanofi Pasteur executive vice-president and global head Thomas Triomphe said: “Today’s presentation of these positive results is another development milestone for providing a safe and effective potential vaccine against SARS-CoV2 and shows how promising this technology is.”

In September, Sanofi and G laxoSmithKline (G SK) initiated a Phase I / II trial to evaluate their adjuvanted recombinant protein-based vaccine candidate against Covid-19.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena